Armenia has become the first country in the world to grant marketing authorizations for Agenus’ botensilimab and balstilimab (BOT+BAL), marking the first approvals of either medicine globally.
The authorizations cover their combined use in adults with microsatellite-stable (MSS) metastatic colorectal cancer without active liver metastases who have previously received available standard therapies, according to an Agenus press release issued on October 8, 2026.
Granted by the Ministry of Health of the Republic of Armenia, the approvals became effective on October 2, 2026. Agenus said they are expected to benefit patients in Armenia and patients who travel to the country for treatment under the care of Armenian oncologists.
For the company’s immunotherapy program, the decision represents a transition from clinical development to the first authorized use of the two medicines as a combination regimen.
What Armenia’s BOT+BAL Approval Covers
Armenian authorities approved botensilimab and balstilimab through separate submissions, with each medicine authorized for use in combination with the other. They are marketed in Armenia as Botvymo and Evamplix, respectively.
The indication specifies MSS metastatic colorectal cancer, prior receipt of available standard therapies, and the absence of active liver metastases. The authorization therefore applies to a defined patient population within the broader colorectal cancer treatment landscape.
Both marketing authorizations are conditional and valid for one year. Renewal will depend on the clinical updates Agenus provides to Armenian regulators annually.
Regulatory Review Included Quality, Clinical Evidence and Safety Monitoring
According to Agenus, Armenian regulatory authorities reviewed the complete registration dossier, submitted in the international Common Technical Document format used under Eurasian Economic Union rules.
The assessment covered product quality and manufacturing, including chemistry, manufacturing and controls; nonclinical evidence; clinical efficacy and safety data; and the pharmacovigilance system and risk management plan.
Garo H. Armen, Chairman and Chief Executive Officer of Agenus, described the decision as a global first for the combination:
“Armenia is the first country in the world to grant marketing approval for BOT+BAL.”
He said the supporting evidence had been published in peer-reviewed journals and presented at major oncology conferences. He thanked Armenia’s health authorities for their review and emphasized the additional treatment option for patients who have exhausted standard therapies.
Clinical Evidence Supporting the Authorizations
The approvals were based on the totality of clinical evidence for BOT+BAL in MSS metastatic colorectal cancer.
The release identifies two studies within the supporting package: mature results from the fully enrolled MSS metastatic colorectal cancer cohort of the Phase 1b C-800-01 study (NCT03860272), and data from the randomized Phase 2 C-800-25 study (NCT05608044).
Agenus highlighted two-year Phase 1b survival findings and randomized Phase 2 evidence in patients without active liver metastases. Results from the clinical program have appeared in Nature Medicine and Clinical Cancer Research, and have been presented at major oncology meetings, including the ASCO Gastrointestinal Cancers Symposium.
The efficacy and safety findings supporting the authorizations are summarized in the approved product information for the two medicines.
How Botensilimab and Balstilimab Work
BOT+BAL combines two antibodies designed to act through complementary immune mechanisms.
Botensilimab is a multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to activate both innate and adaptive antitumor immune responses. Agenus is developing it to extend immunotherapy activity to tumors that have historically responded poorly to conventional immune checkpoint treatments.
According to the company, its mechanisms include priming and activating T cells, reducing regulatory T cells within tumors, activating myeloid cells, and inducing durable immune memory responses.
Balstilimab is a fully human IgG4 monoclonal antibody that blocks PD-1 from interacting with its ligands, PD-L1 and PD-L2. It is designed to sustain antitumor T-cell activity.
Across the broader development program, BOT+BAL has been studied in more than 1,500 patients across more than nine tumor types, spanning late-line refractory disease and early-stage neoadjuvant settings. Agenus’ Phase 3 ROBBIN study is designed to evaluate the combination before surgery in earlier-stage colon cancer.
Approved Regimen and Safety Information
Under Armenia’s approved product information, botensilimab is administered intravenously at 75 mg every six weeks for up to four doses, alongside balstilimab at 240 mg intravenously every two weeks for up to two years, or until disease progression or unacceptable toxicity.
The product information includes warnings and precautions for immune-mediated adverse reactions, including colitis and diarrhea, hepatitis, pneumonitis, endocrinopathies, nephritis, myocarditis and pancreatitis. It also addresses infusion-related reactions.
Agenus stated that healthcare professionals in Armenia should consult the approved product information before prescribing.
Access Beyond Armenia and Potential Regional Applications
The marketing authorizations apply within Armenia’s territory. Following the decision, Agenus will evaluate potential applications for BOT+BAL in MSS metastatic colorectal cancer in other Eurasian Economic Union member countries.
The release also outlines existing access pathways elsewhere. In France, the national Autorisation d’Accès Compassionnel (AAC) program provides fully reimbursed, hospital-based access for eligible patients with MSS metastatic colorectal cancer without active liver metastases, platinum-resistant or platinum-refractory ovarian cancer, and certain advanced soft-tissue sarcomas.
In other countries, physician-initiated named-patient programs provide access under local regulations. BAP Pharma serves as Agenus’ global partner for the French AAC pathway and named-patient programs.
Armenia’s decision establishes the first marketing authorizations for BOT+BAL, while annual clinical updates remain part of the conditional approval framework. For adults meeting the approved criteria, it introduces an authorized combination treatment after available standard therapies; use in other indications and countries remains investigational.
Read further on OncoDaily: Agenus Announces Up to $340M Financing to Advance Phase 3 ROBBIN of Neoadjuvant BOT/BAL in MSS Colon Cancer
